J. C. Bendell

502 total citations
37 papers, 413 citations indexed

About

J. C. Bendell is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. C. Bendell has authored 37 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 18 papers in Molecular Biology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. C. Bendell's work include Cancer Treatment and Pharmacology (13 papers), Lung Cancer Treatments and Mutations (11 papers) and Colorectal Cancer Treatments and Studies (9 papers). J. C. Bendell is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Lung Cancer Treatments and Mutations (11 papers) and Colorectal Cancer Treatments and Studies (9 papers). J. C. Bendell collaborates with scholars based in United States, Canada and Spain. J. C. Bendell's co-authors include H. A. Burris, Suzanne F. Jones, J. R. Infante, Howard A. Burris, Geoffrey I. Shapiro, José Baselga, Yuqin Song, Jordi Rodón, Andrés Cervantes and Desam Roda and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

J. C. Bendell

37 papers receiving 396 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. C. Bendell United States	13	261	208	82	54	53	37	413
P.N. Munster United States	12	307 1.2×	336 1.6×	119 1.5×	79 1.5×	72 1.4×	18	584
Rodrigo Ruiz-Soto United States	9	174 0.7×	186 0.9×	90 1.1×	37 0.7×	92 1.7×	19	408
Corrado Gallo Stampino Italy	12	183 0.7×	238 1.1×	103 1.3×	58 1.1×	32 0.6×	31	419
Tao Osgood United States	6	158 0.6×	185 0.9×	58 0.7×	43 0.8×	32 0.6×	14	308
Shutaro Ozawa Japan	6	263 1.0×	343 1.6×	127 1.5×	126 2.3×	33 0.6×	16	538
Karel Cwiertka Czechia	10	115 0.4×	247 1.2×	123 1.5×	108 2.0×	40 0.8×	45	436
Wendy Cooper United States	8	184 0.7×	162 0.8×	95 1.2×	87 1.6×	20 0.4×	10	393
Lucia Raimondo Italy	8	204 0.8×	185 0.9×	105 1.3×	55 1.0×	36 0.7×	15	387
Joongho Shin United States	8	251 1.0×	324 1.6×	161 2.0×	98 1.8×	149 2.8×	17	567
Amélie Petitprez France	6	178 0.7×	159 0.8×	122 1.5×	75 1.4×	26 0.5×	6	334

Countries citing papers authored by J. C. Bendell

Since Specialization

Citations

This map shows the geographic impact of J. C. Bendell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. C. Bendell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. C. Bendell more than expected).

Fields of papers citing papers by J. C. Bendell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. C. Bendell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. C. Bendell. The network helps show where J. C. Bendell may publish in the future.

Co-authorship network of co-authors of J. C. Bendell

This figure shows the co-authorship network connecting the top 25 collaborators of J. C. Bendell. A scholar is included among the top collaborators of J. C. Bendell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. C. Bendell. J. C. Bendell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sharma, Monica, et al.. (2020). 1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours. Annals of Oncology. 31. S704–S705. 7 indexed citations

Ko, Andrew H., Antonio Cubillo, Madappa N. Kundranda, et al.. (2018). CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer. Annals of Oncology. 29. viii720–viii720. 8 indexed citations

Hurwitz, H., Nikhil Uppal, J. C. Bendell, et al.. (2014). Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial. Annals of Oncology. 25. ii115–ii115. 2 indexed citations

Papadopoulos, Kyriakos P., David S. Mendelson, A. W. Tolcher, et al.. (2011). A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3075–3075. 19 indexed citations

Tolcher, A. W., J. C. Bendell, Amita Patnaik, et al.. (2011). A phase Ib study of the MEK inhibitor GSK1120212 combined with gemcitabine in patients with solid tumors: Interim results.. Journal of Clinical Oncology. 29(4_suppl). 278–278. 9 indexed citations

Ho, Alan L., J. C. Bendell, Gary K. Schwartz, et al.. (2011). Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3033–3033. 27 indexed citations

Donehower, Ross C., Martin Hill, Jessica Bowman, et al.. (2011). A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3091–3091. 7 indexed citations

Raefsky, Eric, David R. Spigel, J. R. Infante, et al.. (2011). Phase II study of NK012 in relapsed small cell lung cancer.. Journal of Clinical Oncology. 29(15_suppl). 7079–7079. 12 indexed citations

Bendell, J. C., Michael Gordon, H. Hurwitz, et al.. (2011). Phase I study of ACE-041, a novel inhibitor of ALK1-mediated angiogenesis, in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3070–3070. 3 indexed citations

10.

Shih, Kuang‐Chung, J. R. Infante, Kyriakos P. Papadopoulos, et al.. (2011). A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 21 days (NCT01214642).. Journal of Clinical Oncology. 29(15_suppl). 2600–2600. 3 indexed citations

11.

Bottino, Dean, Josep Tabernero, Howard A. Burris, et al.. (2011). Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235.. Journal of Clinical Oncology. 29(15_suppl). 3056–3056. 1 indexed citations

12.

Nixon, Andrew B., Mark D. Starr, Hui Pang, et al.. (2010). Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A).. Journal of Clinical Oncology. 28(15_suppl). e21009–e21009. 1 indexed citations

13.

Camacho, Luis H., J. C. Bendell, Luis T. Campos, et al.. (2010). Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). e13008–e13008. 6 indexed citations

14.

Cosimo, Serena Di, J. C. Bendell, Andrés Cervantes, et al.. (2010). A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3008–3008. 47 indexed citations

15.

Yardley, DA, et al.. (2010). Abstract P5-06-06: The Safety and Tolerability of Panobinostat (LBH589) in Combination with Capecitabine +/− Lapatinib: A Phase I Study in HER2+ Breast Cancer. Cancer Research. 70(24_Supplement). P5–6. 2 indexed citations

16.

Peacock, N. W., Suzanne F. Jones, Denise A. Yardley, et al.. (2010). A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.. Journal of Clinical Oncology. 28(15_suppl). 1115–1115. 11 indexed citations

17.

Sharma, Shringi, J. C. Bendell, Michael Gordon, et al.. (2010). Phase I study of ACE-041, a novel inhibitor of vascular maturation, in patients with advanced solid tumors or relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 28(15_suppl). TPS179–TPS179. 3 indexed citations

18.

Jones, Suzanne F., William C. Zamboni, H. A. Burris, et al.. (2009). Phase I and pharmacokinetic (PK) study of IHL-305 (pegylated liposomal irinotecan) in patients with advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 2547–2547. 5 indexed citations

19.

Mears, A., Patricia Creel, J. C. Bendell, et al.. (2007). Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients. Journal of Clinical Oncology. 25(18_suppl). 5039–5039. 12 indexed citations

20.

Czito, Brian G., Christopher Willett, J. C. Bendell, et al.. (2006). 158 Increased toxicity with gefitinib, capecitabine and radiation in pancreatic and rectal cancer: phase I trial results. Radiotherapy and Oncology. 78. S53–S54. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact